• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Neutrophil extracellular traps (NETs) in patients with STEMI. Association with percutaneous coronary intervention and antithrombotic treatments
CONCLUSIONS: NETs were elevated in STEMI patients, increased by pPCI and decreased thereafter. One of the most specific NETs markers was associated with cardiovascular outcomes.PMID:35306431 | DOI:10.1016/j.thromres.2022.03.002
Source: Cell Research - March 20, 2022 Category: Cytology Authors: Maria Ferr é-Vallverdú Ana Mar ía Latorre Mar ía Paz Fuset Elena S ánchez Isabel Madrid Francisco Ten Juana Vall és Mar ía Teresa Santos Santiago Bonanad Antonio Moscard ó Source Type: research

Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in high-bleeding-risk patients with acute coronary syndrome in contemporary practice
CONCLUSIONS: The treatment of bivalirudin showed better efficacy and safety as compared to UFH among patients with ACS undergoing PCI at high risk of bleeding in contemporary practice.PMID:34321166 | DOI:10.1016/j.biopha.2020.110758
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - July 29, 2021 Category: Drugs & Pharmacology Authors: Yahao Zhang Yanghui Zhang Zhiyu Liu Bin Zhang Guizhi Liu Kui Chen Source Type: research

Efficacy and Safety of Bivalirudin During Percutaneous Coronary Intervention in Chronic Total Occlusion: A Retrospective Study
The objective of this study was to examine the efficacy and safety of bivalirudin during percutaneous coronary intervention (PCI) in patients with CTO.METHODS: This trial used a retrospective cohort study design. Medical information from 736 patients with CTO who underwent PCI with bivalirudin or UFH at the First Affiliated Hospital of Zhengzhou University from July 2019 to September 2020 was extracted and analyzed. The primary end point was the 30-day incidence of net adverse clinical events (NACEs), and the secondary end point was the major adverse cardiovascular events (MACEs), which were related to safety and efficacy,...
Source: Clinical Therapeutics - April 3, 2021 Category: Drugs & Pharmacology Authors: Yanghui Zhang Yahao Zhang Chao Chang Shumei Yan Zheng Chen Lishuai Zhang Kui Chen Guizhi Liu Source Type: research

Bivalirudin in patients undergoing percutaneous coronary intervention and independent predictors of postoperative adverse events in these patients: A real world retrospective study
The efficacy and safety of bivalirudin in percutaneous coronary intervention (PCI) has always been a hot topic in perioperative antithrombotic therapy, but there are still some controversies. So studies are needed to provide more evidence, especially the real world study which includes patients excluded from previous RCT studys. Our study aimed to investigate these information and analyze the independent predictors of postoperative adverse events. A retrospective study enrolled 1416 patients underwent PCI in Tianjin Chest Hospital from May 2016 to October 2017. The incidence of stent-thrombosis and net clinical adverse ...
Source: Medicine - March 12, 2021 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research

Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial
Publication date: Available online 25 August 2018Source: The LancetAuthor(s): Marco Valgimigli, Enrico Frigoli, Sergio Leonardi, Pascal Vranckx, Martina Rothenbühler, Matteo Tebaldi, Ferdinando Varbella, Paolo Calabrò, Stefano Garducci, Paolo Rubartelli, Carlo Briguori, Giuseppe Andó, Maurizio Ferrario, Ugo Limbruno, Roberto Garbo, Paolo Sganzerla, Filippo Russo, Marco Nazzaro, Alessandro Lupi, Bernardo CorteseSummaryBackgroundThe Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of Angiox (MATRIX) programme was designed to assess the comparative safety and effectiveness of ra...
Source: The Lancet - August 25, 2018 Category: General Medicine Source Type: research

Efficacy and safety of bivalirudin for percutaneous coronary intervention in acute coronary syndromes: a meta-analysis of randomized-controlled trials
ConclusionsCompared with heparin, bivalirudin was associated with a similar incidence of ischemic events following PCI for ACS. An association of bivalirudin with decreased bleeding was not seen with balanced use of GPI.
Source: Clinical Research in Cardiology - April 13, 2018 Category: Cardiology Source Type: research

Comparison of Heparin and Bivalirudin in Patients Undergoing Orbital Atherectomy.
CONCLUSION: Both heparin and bivalirudin were safe and effective antithrombotic agents for patients who underwent orbital atherectomy. A randomized trial is needed to determine the antithrombotic agent of choice for orbital atherectomy. PMID: 29086730 [PubMed - in process]
Source: The Journal of Invasive Cardiology - November 2, 2017 Category: Cardiology Tags: J Invasive Cardiol Source Type: research

Outcomes in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction Via Radial Access Anticoagulated With Bivalirudin Versus Heparin: A Report From the National Cardiovascular Data Registry
Conclusions In patients undergoing primary PCI via transradial access anticoagulated with bivalirudin or heparin, there was no difference in the composite endpoint of death, myocardial infarction, or stroke.
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - June 5, 2017 Category: Cardiology Authors: Jovin, I. S., Shah, R. M., Patel, D. B., Rao, S. V., Baklanov, D. V., Moussa, I., Kennedy, K. F., Secemsky, E. A., Yeh, R. W., Kontos, M. C., Vetrovec, G. W. Tags: Coronary Source Type: research

Effect of postprocedural full ‐dose infusion of bivalirudin on acute stent thrombosis in patients with ST‐elevation myocardial infarction undergoing primary percutaneous coronary intervention: Outcomes in a large real‐world population
ConclusionPost‐PCI full‐dose bivalirudin infusion is safe and has a trend to protect against acute ST in STEMI patients undergoing primary PCI in real‐world settings.
Source: Cardiovascular Therapeutics - May 12, 2017 Category: Cardiology Authors: Heyang Wang, Zhenyang Liang, Yi Li, Bin Li, Junming Liu, Xueyi Hong, Xin Lu, Jiansheng Wu, Wei Zhao, Qiang Liu, Jian An, Linfeng Li, Fanli Pu, Qiang Ming, Yaling Han Tags: ORIGINAL RESEARCH ARTICLE Source Type: research

Comparison of antithrombotic agents during urgent percutaneous coronary intervention following thrombolytic therapy: A retrospective cohort study
ConclusionIn STEMI patients undergoing PCI within 24 hr after thrombolytic therapy, bivalirudin was associated with a strong trend toward reduced bleeding complications as compared to heparin alone or heparin plus GPI.The optimal antithrombotic regiment for urgent PCI following thrombolytic therapy is currently unknown. Our study demonstrated that use of bivalirudin during PCI following thrombolytic therapy is associated with a trend toward reduced bleeding complications compared to heparin alone or heparin plus GPI. Large randomized trials of adjunctive anticoagulation during PCI in this complex post‐thrombolytic popula...
Source: Catheterization and Cardiovascular Interventions - April 18, 2017 Category: Cardiovascular & Thoracic Surgery Authors: Jaya R. Mallidi, Peter Robinson, Paul F. Visintainer, Amir S. Lotfi, Scott Mulvey, Gregory R. Giugliano Tags: Coronary Artery Disease Source Type: research

Effect of Post ‐procedural Full Does Infusion of Bivalirudin on Acute Stent Thrombosis in Patients with ST‐elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Outcomes in a large real‐world population
ConclusionPost‐PCI full‐does bivalirudin infusion is safe and has a trend to protect against acute ST in STEMI patients undergoing primary PCI in real world settings.This article is protected by copyright. All rights reserved.
Source: Cardiovascular Therapeutics - January 13, 2017 Category: Cardiology Authors: Heyang Wang, Zhenyang Liang, Yi Li, Bin Li, Junming Liu, Xueyi Hong, Xin Lu, Jiansheng Wu, Wei Zhao, Qiang Liu, Jian An, Linfeng Li, Fanli Pu, Qiang Ming, Yaling Han Tags: Original Research Article Source Type: research

Unfractionated heparin versus bivalirudin in patients undergoing primary percutaneous coronary intervention: a SWEDEHEART study.
CONCLUSIONS: In this large, nationwide observational study we found low and similar rates of early ST in UFH only and bivalirudin treated patients undergoing primary PCI. Mortality was higher in UFH compared with bivalirudin treated patients. PMID: 28044990 [PubMed - as supplied by publisher]
Source: EuroIntervention - January 5, 2017 Category: Cardiovascular & Thoracic Surgery Tags: EuroIntervention Source Type: research

Efficacy and safety of prehospital administration of unfractionated heparin, enoxaparin or bivalirudin in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Insights from the ORBI registry.
CONCLUSION: In this prospective registry, there were no significant differences in the rates of in-hospital MACE or major bleeding after prehospital initiation of UFH, enoxaparin or bivalirudin in patients treated by primary PCI for STEMI. PMID: 27818120 [PubMed - as supplied by publisher]
Source: Archives of Cardiovascular Diseases - November 2, 2016 Category: Cardiology Authors: Auffret V, Leurent G, Boulmier D, Bedossa M, Zabalawi A, Hacot JP, Coudert I, Filippi E, Castellant P, Rialan A, Rouault G, Druelles P, Boulanger B, Treuil J, Avez B, Le Guellec M, Gilard M, Le Breton H Tags: Arch Cardiovasc Dis Source Type: research

Effectiveness and Safety of Bivalirudin During Percutaneous Coronary Intervention in Acute Coronary Syndrome in the Real World: CARTAGOMAX Study
Abstract: The CARTAGOMAX study assessed the safety and efficacy of bivalirudin during real-world cardiac intervention. This was a single-center prospective study. Patients with acute coronary syndrome undergoing percutaneous coronary intervention were anticoagulated with bivalirudin alone or unfractionated heparin plus a glycoprotein IIb/IIIa inhibitor. Propensity score matching was performed to control for baseline imbalances and yielded 1168 patients. There was lower incidence of the composite outcome of death from any cause or major bleeding at 30 days (P = 0.005), 6 months (P = 0.005), and 12 months (P = 0.001) of foll...
Source: Journal of Cardiovascular Pharmacology - September 1, 2016 Category: Cardiology Tags: Original Article Source Type: research

Pages: 1  2